Trans women are at high risk of HIV infection. We conducted a review to determine the extent to which trans women were eligible for inclusion in and enrolled into pre-exposure prophylaxis (PrEP) efficacy trials. Out of seven trials analyzing PrEP efficacy, we found that trans women comprised only 1.2
作者：Daniel J, Escudero；Thomas, Kerr；Don, Operario；Maria E, Socías；Omar, Sued；Brandon D L, Marshall
来源：AIDS care 2015 年 27卷 5期
